openPR Logo
Press release


04-17-2008 05:52 PM CET | Health & Medicine

Press release from: Affiris

Vienna, 17. April 2008. The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.

Due to the dramatic increase in the number of Alzheimer's cases, new and more effective treatments are urgently needed. The medicines that are currently in use are of limited value as they can only alleviate the symptoms of the disease temporarily, for a period of around one to two years, and are ultimately unable to prevent the onset of dementia. However, the Viennese biotech company Affiris is pursuing a new approach, which is yielding extremely promising results. The company is using an innovative Alzheimer’s vaccine not just to target the symptoms of the disease, but in the hope of directly modifying the disease process in the brain of Alzheimer's patients.

Safety is the number one priority in the current clinical trials that are being carried out on patients. "The current studies are focused on establishing the safety and tolerability of the new vaccines," emphasises Prof. Achim Schneeberger, Head of Clinical Department at Affiris. The new vaccines are currently being tested in two Alzheimer's trials. The AFFiRiS 001 trial is being staged at the Vienna General Hospital (AKH) and is testing the vaccine AFFITOP AD01. The AFFiRiS 002 trial of the vaccine AD02 is being conducted at the Institute of Psychosomatic Medicine, Vienna. Although the two vaccines have different active ingredients – the antigenic peptide – both trials are virtually identical in terms of their design. Interim toxicity findings from the AFFiRiS 001 trial, which began in September 2007 and involves to date 9 Alzheimer’s patients with mild to moderate dementia, indicate that the innovative immunotherapy is safe. Prof. Schneeberger explains: "All the patients have thus far tolerated the vaccines extremely well, as expected." The AFFiRiS 002 sister trial also got off to a similarly promising start at the end of February 2008 - all of the Alzheimer’s patients that have been involved in the trial have also received and tolerated their first vaccinations.

The Aß amyloid is the main component in the protein deposits (amyloid plaques) that are characteristic of Alzheimer's dementia. The accumulation of this amyloid in the form of neurotoxic aggregates destroys brain cells and causes the typical symptoms of Alzheimer's disease. During the 2001 trial of a previous Alzheimer's vaccine called AN1792, which was conducted by the U.S. and Irish pharmaceutical alliance ELAN-Wyeth, patients suffered severe inflammation of the brain and the trial was immediately halted. Despite this, follow-up analyses showed that the vaccine had been effective in some of the patients. Around 20 percent of those who received the vaccine developed antibodies that protected against the Aß amyloid and disease progression was halted in a number of the patients.

"Our Vienna-based research group is in the process of modifying the immunogen for the vaccine," explains Prof. Schneeberger. Scientists at Affiris are also using an ingenious approach based on the principle of molecular mimicry to exclude potential unwanted side effects in advance. This technology allows the intended immune reaction to be accurately directed against harmful protein deposits. A multifaceted approach to safety means that this "immunological camouflage" is supported by a combination of additional safety components developed by Affiris. These include the immunogenic peptide, a carrier protein and a proven and safe adjuvant (vaccine additive). The peptides in use are short mimotopes of the Aß amyloid that are between six and seven amino acids long. While this should permit the breakup of harmful proteins in the brain, it should also prevent any undesired immune reactions. An animal model used by Affiris for Alzheimer’s dementia not only confirmed that the vaccine can reduce amyloid plaques by around 70 percent, but also showed that the animals performed significantly better in brain function tests after treatment. The first clinical trials on Alzheimer's patients have now also indicated that this concept works extremely well. As all the patients treated so far have tolerated the vaccine without any noteworthy complications, the way is now open for the next stage of testing. This milestone also means that the vaccine developed by Affiris is one of the best hopes in the fight against Alzheimer's disease.

PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna, Austria
T +43 / 1 / 505 70 44

AFFIRIS - research for better health
Affiris is a young and innovative Vienna-based biotechnology company which has been operating from Campus Vienna Biocenter since 2003 and employs more than 30 highly skilled staff. The company has an international outlook and collaborates with partner centres in Germany, Spain, the U.K. and the U.S. "Our research work focuses on the development of treatments for diseases that urgently require a medical solution. Alongside the Alzheimer's programme, we at Affiris are also working to develop and make available new medicines for the treatment of other major diseases such as atherosclerosis in the near future," explains scientist, founding member and CEO of Affiris GmbH, Dr. Walter Schmidt.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AFFIRIS DEVELOPS ALZHEIMER'S VACCINE here

News-ID: 42314 • Views: 1451

More Releases from Affiris

04-30-2014 | Health & Medicine
Parkinson's Vaccine – Top Experts Unite in European Consortium
EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel.
Vienna, 25 September 2008. The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to
Vienna, Austria, 28 April 2008: According to an analysis carried out by Lifescience-online, due to it\'s AFFITOME technology AFFiRiS GmbH could become a major player in the global pharmaceutical industry. After looking at data from a total of 67 European biotech companies, the study picked out the five firms with the most innovative approaches to therapy and most intensive R&D activities for closer analysis. AFFiRiS GmbH came top of this
07-19-2007 | Health & Medicine
Affiris begins clinical testing of Alzheimer's vaccine
Vienna, 19th July 2007. The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the first time. This development means that the 8.5 million-Euro venture capital finance agreement the company concluded with Munich-based MIG-Fonds in April 2006 has reached a key milestone

All 5 Releases

More Releases for Alzheimer

Alzheimer Disease Drugs Market Global Trends, Market Share, Industry Size, Growt …
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently
Anti-β-Alzheimer Therapies Market Analysis with Technological Advancement and G …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as